Pharming's Joenja Receives EU Marketing Authorization for APDS, First Treatment in Europe
PHAR sits 45% above its 52-week low of $8.689.
Summary
Pharming Group N.V. announced that the European Commission has granted marketing authorization for Joenja (leniolisib), making it the first approved treatment for APDS in the European Union.
Key Events · Product Development and Regulatory · PHAR
-
EU Marketing Authorization Granted
The European Commission has granted marketing authorization for Joenja® (leniolisib) for the treatment of Activated PI3K delta Syndrome (APDS) in adult and pediatric patients aged 12 years and older.
-
First Approved Treatment in EU
Joenja is now the first and only approved treatment for APDS in the European Union, addressing a significant unmet medical need for patients with this rare primary immunodeficiency.
-
European Launch Expected Q3 2026
The first European launch of Joenja is anticipated in Germany in Q3 2026, with further launches across the EU pending national reimbursement negotiations.
-
Global Expansion Continues
This approval expands Joenja's market presence, adding to existing authorizations in the United States, United Kingdom, Japan, Australia, and Israel, reinforcing Pharming's global strategy.
Analysis · PHAR · Life Sciences
This final marketing authorization from the European Commission for Joenja (leniolisib) is a critical milestone for Pharming, opening up the significant European market for its rare disease drug. As the first approved treatment for Activated PI3K delta Syndrome (APDS) in the EU, it addresses a high unmet medical need and is expected to drive substantial revenue growth, with the first launch anticipated in Germany in Q3 2026.
At the time of this filing, PHAR was trading at $12.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $918M. The 52-week trading range was $8.69 to $21.34. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.